To document subtype-specific clinical features of lymphoma of the eyelid, and their effect on patient outcome.
Retrospective observational case series.
Patient data were collected from 7 international eye cancer centers from January 1, 1980 through December 31, 2015. The cases included primary and secondary lymphomas affecting the eyelid. Overall survival, disease-specific survival (DSS), and progression-free survival were the primary endpoints.
Eighty-six patients were included. Mean age was 63 years and 47 (55%) were male. Non-Hodgkin B-cell lymphomas constituted 83% (n?= 71) and T-cell lymphomas constituted 17% (n?= 15). The most common subtypes were extranodal marginal-zone lymphoma (EMZL) (37% [n?= 32]), follicular lymphoma (FL) (23% [n?= 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n?= 9]), mantle cell lymphoma (MCL) (8% [n?= 7]), and mycosis fungoides (MF) (9% [n?= 8]). EMZL had a female predilection (69% [22 of 32]), whereas MCL (71% [5 of 7]) and?MF (88% [7 of 8]) had a male predominance. MCL (57% [4 of 7]), DLBCL (56% [5 of 9]), and MF (88% [7 of 8]) were frequently secondary lymphomas. Localized EMZL and FL were mostly treated with external beam radiation therapy, whereas DLBCL, MCL, and high Ann Arbor stage EMZL and FL were frequently treated with chemotherapy. DLBCL and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively), whereas EMZL, FL, and MF had a good prognosis (5-year DSS, 88%, 88% and 86%, respectively).
Lymphoma of the eyelid consists mainly of the lymphoma subtypes EMZL, FL, DLBCL, MCL, and MF. High-grade DLBCL and MCL, as well as MF, are frequently secondary eyelid lymphomas. The main predictor of outcome was the histologic subtype: EMZL, FL, and MF had a significantly better prognosis than MCL and DLBCL.